These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 26289851)
1. Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer. Haghpanah V; Fallah P; Tavakoli R; Naderi M; Samimi H; Soleimani M; Larijani B Tumour Biol; 2016 Jan; 37(1):1299-308. PubMed ID: 26289851 [TBL] [Abstract][Full Text] [Related]
2. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma. Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090 [TBL] [Abstract][Full Text] [Related]
3. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression. Sheng W; Chen Y; Gong Y; Dong T; Zhang B; Gao W Oncol Rep; 2016 Dec; 36(6):3387-3396. PubMed ID: 27779717 [TBL] [Abstract][Full Text] [Related]
4. Thyroid Follicular Cell Loss of Differentiation Induced by MicroRNA miR-17-92 Cluster Is Attenuated by CRISPR/Cas9n Gene Silencing in Anaplastic Thyroid Cancer. Fuziwara CS; Saito KC; Kimura ET Thyroid; 2020 Jan; 30(1):81-94. PubMed ID: 31578932 [No Abstract] [Full Text] [Related]
5. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer. Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531 [TBL] [Abstract][Full Text] [Related]
6. Cancer stem-like cell behavior in anaplastic thyroid cancer: A challenging dilemma. Haghpanah V; Fallah P; Naderi M; Tavakoli R; Soleimani M; Larijani B Life Sci; 2016 Feb; 146():34-9. PubMed ID: 26772823 [TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma. Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533 [TBL] [Abstract][Full Text] [Related]
9. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells. Mio C; Conzatti K; Baldan F; Allegri L; Sponziello M; Rosignolo F; Russo D; Filetti S; Damante G Oncol Rep; 2018 Feb; 39(2):582-588. PubMed ID: 29251329 [TBL] [Abstract][Full Text] [Related]
10. Inverse Agonist of Estrogen-Related Receptor γ Enhances Sodium Iodide Symporter Function Through Mitogen-Activated Protein Kinase Signaling in Anaplastic Thyroid Cancer Cells. Singh TD; Jeong SY; Lee SW; Ha JH; Lee IK; Kim SH; Kim J; Cho SJ; Ahn BC; Lee J; Jeon YH J Nucl Med; 2015 Nov; 56(11):1690-6. PubMed ID: 26338896 [TBL] [Abstract][Full Text] [Related]
12. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma. Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724 [TBL] [Abstract][Full Text] [Related]
13. Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy. Reddi HV; Driscoll CB; Madde P; Milosevic D; Hurley RM; McDonough SJ; Hallanger-Johnson J; McIver B; Eberhardt NL Cancer Gene Ther; 2013 May; 20(5):267-75. PubMed ID: 23598436 [TBL] [Abstract][Full Text] [Related]
14. Effects of nutraceuticals on anaplastic thyroid cancer cells. Allegri L; Rosignolo F; Mio C; Filetti S; Baldan F; Damante G J Cancer Res Clin Oncol; 2018 Feb; 144(2):285-294. PubMed ID: 29197967 [TBL] [Abstract][Full Text] [Related]
15. miR-4295 promotes cell proliferation and invasion in anaplastic thyroid carcinoma via CDKN1A. Shao M; Geng Y; Lu P; Xi Y; Wei S; Wang L; Fan Q; Ma W Biochem Biophys Res Commun; 2015 Sep; 464(4):1309-1313. PubMed ID: 26231799 [TBL] [Abstract][Full Text] [Related]
16. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Takakura S; Mitsutake N; Nakashima M; Namba H; Saenko VA; Rogounovitch TI; Nakazawa Y; Hayashi T; Ohtsuru A; Yamashita S Cancer Sci; 2008 Jun; 99(6):1147-54. PubMed ID: 18429962 [TBL] [Abstract][Full Text] [Related]
17. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression. Yan P; Su Z; Zhang Z; Gao T Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599 [TBL] [Abstract][Full Text] [Related]
18. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572 [TBL] [Abstract][Full Text] [Related]
19. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells. Orlandella FM; Di Maro G; Ugolini C; Basolo F; Salvatore G Oncotarget; 2016 Oct; 7(43):70575-70588. PubMed ID: 27661106 [TBL] [Abstract][Full Text] [Related]
20. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC). Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]